R-Pharm

Quick facts

Marketed products

• Tavanic · Other

Phase 3 pipeline

• Ixabepilone + Capecitabine · Oncology
  Ixabepilone stabilizes microtubules to prevent cell division, while capecitabine is a prodrug that converts to fluorouracil to inhibit DNA synthesis, together providing synergistic cytotoxic activity against cancer cells.
• Odelepan · Other
• Placebo (100 ml)
  This drug has no known mechanism of action.
• Placebo (250 ml)
  This drug has no known mechanism of action.
• Placebo Narlaprevir · Infectious Diseases
  Narlaprevir is a protease inhibitor used to treat hepatitis C virus (HCV) infection.
• RPH-002
  RPH-002 is a small molecule that targets the [insert target here, if known].
• RPH-051 · Immunology
  RPH-051 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• RPH-075
  RPH-075 is a small molecule that targets the [insert target here, if known].
• standard concomitant therapy · Oncology
  Standard concomitant therapy involves administering multiple medications together to treat a condition.
• Uritos® · Rheumatology / Metabolic Disorders
  Uritos is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.
• Urotol® · Urology
  Urotol is a muscarinic receptor antagonist used to treat overactive bladder.

Phase 2 pipeline

• Epothilone · Other
• rAd26-S
• Refralon · Other

Phase 1 pipeline

• Ixabepilone, 25 mg, with famotidine
• Ixabepilone, 25 mg, with food
• RPH-001

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• R-Pharm portfolio CI brief
• R-Pharm pipeline updates RSS